Clinical Trials Directory

Trials / Completed

CompletedNCT03361280

Removal of Beta Blocker Drugs by Hemodialysis

Beta-blocker Dialyzability in Maintenance Hemodialysis Patients

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
8 (actual)
Sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Eight maintenance hemodialysis patients are given one of four beta blocker drugs (atenolol, bisoprolol, carvedilol, metoprolol) three hours prior to a hemodialysis session. Blood samples and spent dialysate are collected during dialysis. On separate dialysis sessions, patients received the other study drugs until they have taken each of the four study drugs. Dialytic clearance is calculated.

Conditions

Interventions

TypeNameDescription
DRUGBeta blockerBeta blockers are administered as described in arms.

Timeline

Start date
2015-02-27
Primary completion
2016-03-10
Completion
2016-03-10
First posted
2017-12-04
Last updated
2017-12-04

Source: ClinicalTrials.gov record NCT03361280. Inclusion in this directory is not an endorsement.

Removal of Beta Blocker Drugs by Hemodialysis (NCT03361280) · Clinical Trials Directory